These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31480372)

  • 1. Ultra-Mutation in
    Barresi V; Simbolo M; Mafficini A; Piredda ML; Caffo M; Cardali SM; Germanò A; Cingarlini S; Ghimenton C; Scarpa A
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31480372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
    Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
    Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.
    Cantero D; Mollejo M; Sepúlveda JM; D'Haene N; Gutiérrez-Guamán MJ; Rodríguez de Lope Á; Fiaño C; Castresana JS; Lebrun L; Rey JA; Salmon I; Meléndez B; Hernández-Laín A
    Neurooncol Adv; 2020; 2(1):vdz059. PubMed ID: 32642724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
    Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
    Hodges TR; Ott M; Xiu J; Gatalica Z; Swensen J; Zhou S; Huse JT; de Groot J; Li S; Overwijk WW; Spetzler D; Heimberger AB
    Neuro Oncol; 2017 Aug; 19(8):1047-1057. PubMed ID: 28371827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas.
    Cho YA; Kim D; Lee B; Shim JH; Suh YL
    J Neurooncol; 2021 May; 153(1):43-53. PubMed ID: 33864561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma.
    Richardson TE; Yokoda RT; Rashidipour O; Vij M; Snuderl M; Brem S; Hatanpaa KJ; McBrayer SK; Abdullah KG; Umphlett M; Walker JM; Tsankova NM
    Neurooncol Adv; 2023; 5(1):vdad085. PubMed ID: 37554222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme.
    Martinez R; Schackert HK; Appelt H; Plaschke J; Baretton G; Schackert G
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):87-93. PubMed ID: 15672285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative transcriptome analysis identified a BMP signaling pathway-regulated lncRNA AC068643.1 in IDH mutant and wild-type glioblastomas.
    Huang GH; Pei YC; Yang L; Mou KJ; Tang JH; Xiang Y; Liu J; Lv SQ
    Oncol Lett; 2020 Jul; 20(1):75-84. PubMed ID: 32565936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
    Ho WM; Chen CY; Chiang TW; Chuang TJ
    Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma.
    Poon CC; Gordon PMK; Liu K; Yang R; Sarkar S; Mirzaei R; Ahmad ST; Hughes ML; Yong VW; Kelly JJP
    Oncotarget; 2019 May; 10(33):3129-3143. PubMed ID: 31139325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
    Wang PF; Song HW; Cai HQ; Kong LW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2017 Jul; 8(30):50117-50123. PubMed ID: 28223536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients.
    Neumann JE; Dorostkar MM; Korshunov A; Mawrin C; Koch A; Giese A; Schüller U
    J Neuropathol Exp Neurol; 2016 May; 75(5):408-14. PubMed ID: 26975364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme.
    Martinez R; Schackert HK; Plaschke J; Baretton G; Appelt H; Schackert G
    Oncology; 2004; 66(5):395-403. PubMed ID: 15331927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of glioblastomas and immune microenvironment in a Chinese family with Lynch syndrome and concurrent porokeratosis.
    Yao ZG; Hua F; Yin ZH; Xue YJ; Hou YH; Nie YC; Zheng ZM; Zhao MQ; Guo XH; Ma C; Li XK; Wang Z; Liu GC; Zhang GH
    Front Oncol; 2023; 13():1194232. PubMed ID: 37529690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.